Key facts
- Groundwork BioAg’s last known valuation is $69.7M (Jun 2022).
- It has raised $59.6M; the latest was Later Stage VC ($20.0M) in Jan 2025.
- Notable investors include Ibex Investors, BASF Venture Capital, Meach Cove Capital, HSBC Asset Management, Middleland Capital — 20 tracked in total.
- Status: Privately Held (backing).
Leadership
- Alon WerberChief Executive Officer
- Bari RuimyChief Financial Officer
- Danny LevyChief Technology Officer & Vice President
- Hanan DorExecutive Officer
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Groundwork BioAg
- ·The full record, as it builds
Funding rounds
No funding rounds for Groundwork BioAg are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Groundwork BioAg
Developer of a bioagriculture platform designed to enhance soil health and carbon sequestration through mycorrhizal technology. The company offers scalable mycorrhizal inoculants and nature-based carbon integration methods, enabling commercial and regenerative farmers to improve crop yields, reduce fertilizer use, and generate carbon credit revenue.
- Sector
- Healthcare
- HQ
- Mazor, Israel
- Founded
- 2014
- Employees
- 53
- Website
- groundworkbioag.com/
- Ownership
- Privately Held (backing)
Groundwork BioAg doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Groundwork BioAg shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Groundwork BioAg in its N-PORT filings yet. We sweep new filings monthly.